LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Corvus Pharmaceuticals, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERCRVS
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / CRVS COVERAGE

What’s moving Corvus Pharmaceuticals, Inc. now

Current reporting with the operating signal separated from the noise.

01
Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

The story matters when it changes Corvus Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript

Investors are testing whether Corvus Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

Investors are testing whether Corvus Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call Transcript

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call Transcript

Investors are testing whether Corvus Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
A number of insiders bought Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) stock last year, which is great news for shareholders

A number of insiders bought Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) stock last year, which is great news for shareholders

Investors are testing whether Corvus Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
06
Corvus Pharmaceuticals, Inc.'s stock is down 23%, but insiders still have about US$29k in profit after buying earlier this year

Corvus Pharmaceuticals, Inc.'s stock is down 23%, but insiders still have about US$29k in profit after buying earlier this year

Investors are testing whether Corvus Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
07
Earnings Call Transcript

Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q1 2019 Results

The story matters when it changes Corvus Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest CRVS filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-07 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-04 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-12 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-22 · Period 2026-07-21SEC ↗8-KMaterial company eventFiled 2026-06-12 · Period 2026-06-11SEC ↗8-KMaterial company eventFiled 2026-05-14 · Period 2026-05-14SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-24 · Period 2026-06-11SEC ↗SCHEDULE 13G/AOfficial SEC filingFiled 2026-07-27SEC ↗
EARNINGS / QUARTERLY TRACKER

Corvus Pharmaceuticals, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.